S&P: Merck on Watch for Debt Downgrade
The rating agency's big concern: the magnitude of possible litigation against the AAA-rated drugmaker after its Vioxx withdrawal
By Arthur Wong
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.